Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by LifeGoesOn1973on Sep 24, 2019 8:43am
262 Views
Post# 30158067

RRR for 3 point MACE is not lower than RRR for 5 points MACE

RRR for 3 point MACE is not lower than RRR for 5 points MACE
and this is proved in Amarin study where the RRR for 5 points MACE was 25% and the RRR for 3 points MACE was 26%, and it makes sense coz the lower number of events is affecting BOTH the placebo and the treated group, hence the impact on the RRR % itself is not there. I know that Bear yesterday broke down the phase II between 5 points MACE and 3 points MACE showing that the 3 point RRR was lower than the 5 points RRR for the overall group, but it was even higher when he applied that to the Diabetic group, so in a big pool and a longer duration I don't think you can confirm that RRR for 3 points will be lower than the 5 points, especially that the longer the duration the better our drug works.
Bullboard Posts